In recent years, the market scale of immunodiagnostic reagents in China has been increasing year by year. In 2020, the market size of China's immunodiagnostic reagent industry reached 32.1 billion yuan, an increase of 24.42% year-on-year.

POCT industry started late in China, the overall market size is still small currently, and the penetration rate in hospitals and other terminal sites is low, so there is a huge potential development space. Qianzhan Institute predicts that from 2022-2027, the Chinese POCT market will rise by about 9% CAGR to about 18 billion yuan in 2027.

As the world's most active emerging market, the influence of China's market on the entire global scientific instrument market is rising year by year, and revenue in China has become the most important part of the global performance of many multinational companies.

On March 30 2023, Kalorama Information indicates that the global IVD market is now over $124 billion, with operations in more than 20 key healthcare and medical areas, such as infectious disease immunoassays, POC, molecular microbiology, clinical chemistry, etc.

Looking at the overall environment, the receding of the COVID-19 testing dividend, the slowdown of conventional business growth, and the pressure from the collection policy have all brought the IVD industry into an adjustment period.

According to Kalorama estimates, the Romanian IVD market, serving 18.8 million residents, grew to $464 million in 2022.

Blood gas diagnosis mainly involves measuring the pH value, pCO2, pO2, and other gases dissolved in human blood to understand the body's respiratory function and acid-base balance status.

Chinese immunodiagnostics market has maintained an overall growth rate of approximately 20% over the past five years, and is expected to reach a market size of CNY 52.4 billion in 2022.

Which segmentations will have a broader development prospect in the Chinese IVD field?

Recently, executives from multinational medical enterprises intensively visited China or revealed their plans to visit China. It is becoming a common question for most multinational medical businesses to explore how to support China's high-level opening up.